Acceleron's sotatercept nabs Orphan Drug tag for PAH in Europe

 

• The European Commission has granted Orphan Designation to Acceleron Pharma's (NASDAQ:XLRN) sotatercept for the treatment of pulmonary arterial hypertension (PAH).
• The company is currently advancing a Phase 3 trial for sotatercept, beginning with the registrational trial known as STELLAR expected to initiate by the end of this year.
• Sotatercept is part of a licensing agreement with Bristol Myers Squibb, and a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR-II signaling, which is a key molecular driver of pulmonary arterial hypertension.
• https://seekingalpha.com/news/3643957-accelerons-sotatercept-nabs-orphan-drug-tag-for-pah-in-europe